MRI in High-Grade Glioma Patients Undergoing Chemoradiation (NCT05212272)
A Feasibility Study of Interim PET-MRI in High-grade Glioma Patients Undergoing Chemoradiation
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, optional lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (13 items).
Location: Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
- PET-MRI Brain Scan (PROCEDURE)
- Blood draw (DIAGNOSTIC_TEST)
- Memory testing (BEHAVIORAL)
- Optional lumbar puncture for cerebrospinal fluid collection (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Does not speak or read English
- Unable to participate in cognitive testing due to aphasia or other severe cognitive impairment as determined by the PI, or Dr. Cummings or her designee.
- Unable to give informed consent
- Past medical history of any kind of dementia or diagnosed with mild cognitive impairment prior to diagnosis with their brain tumor
- Unable to safely fast for 8 hours prior to bloodwork or 6 hours prior to PET scan
- Currently taking cognition-enhancing medications including:
- Donepezil
- Memantine
- Armodafinil
- Methylphenidate
- Pregnant or nursing mothers.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
📞 Contact the Study Coordinator
Phone: (336) 716-5772
Email: Christina.Cramer@wfusm.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in High Grade Glioma
- PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma — Aurora, Colorado
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors — Aurora, Colorado
- A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion — Aurora, Colorado
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion — Aurora, Colorado
- A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) — Toronto, Ontario
Explore by condition: All High Grade Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.